Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:TUFT1-KMT2E

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: TUFT1-KMT2E
	FusionPDB ID: 95434
	FusionGDB2.0 ID: 95435
		Hgene	Tgene
	Gene symbol	TUFT1	KMT2E
	Gene ID	7286	55904
	Gene name	tuftelin 1	lysine methyltransferase 2E (inactive)
	Synonyms	-	HDCMC04P\|MLL5\|NKp44L\|ODLURO
	Cytomap	1q21.3	7q22.3
	Type of gene	protein-coding	protein-coding
	Description	tuftelin	inactive histone-lysine N-methyltransferase 2Ehistone-lysine N-methyltransferase 2Ehistone-lysine N-methyltransferase MLL5inactive lysine N-methyltransferase 2Elysine (K)-specific methyltransferase 2Emyeloid/lymphoid or mixed-lineage leukemia 5 (trit
	Modification date	20200313	20200314
	UniProtAcc	.	Q8IZD2 Main function of 5'-partner protein: FUNCTION: Associates with chromatin regions downstream of transcriptional start sites of active genes and thus regulates gene transcription (PubMed:23629655, PubMed:24130829, PubMed:23798402). Chromatin interaction is mediated via the binding to tri-methylated histone H3 at 'Lys-4' (H3K4me3) (PubMed:24130829, PubMed:23798402). Key regulator of hematopoiesis involved in terminal myeloid differentiation and in the regulation of hematopoietic stem cell (HSCs) self-renewal by a mechanism that involves DNA methylation (By similarity). Also acts as an important cell cycle regulator, participating in cell cycle regulatory network machinery at multiple cell cycle stages including G1/S transition, S phase progression and mitotic entry (PubMed:14718661, PubMed:18573682, PubMed:19264965, PubMed:23629655). Recruited to E2F1 responsive promoters by HCFC1 where it stimulates tri-methylation of histone H3 at 'Lys-4' and transcriptional activation and thereby facilitates G1 to S phase transition (PubMed:23629655). During myoblast differentiation, required to suppress inappropriate expression of S-phase-promoting genes and maintain expression of determination genes in quiescent cells (By similarity). {ECO:0000250\|UniProtKB:Q3UG20, ECO:0000269\|PubMed:14718661, ECO:0000269\|PubMed:18573682, ECO:0000269\|PubMed:23629655, ECO:0000269\|PubMed:23798402, ECO:0000269\|PubMed:24130829}.; FUNCTION: [Isoform NKp44L]: Cellular ligand for NCR2/NKp44, may play a role as a danger signal in cytotoxicity and NK-cell-mediated innate immunity. {ECO:0000269\|PubMed:23958951}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000353024, ENST00000368848, ENST00000368849, ENST00000392712, ENST00000538902,	ENST00000476671, ENST00000480368, ENST00000257745, ENST00000311117, ENST00000334877, ENST00000334914,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	10 X 6 X 10=600	7 X 10 X 3=210
	# samples	13	10
	** MAII score	log2(13/600*10)=-2.20645087746743 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(10/210*10)=-1.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: TUFT1 [Title/Abstract] AND KMT2E [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: TUFT1 [Title/Abstract] AND KMT2E [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	KMT2E(104748372)-TUFT1(151542133), # samples:1 TUFT1(151538704)-KMT2E(104749389), # samples:1
Anticipated loss of major functional domain due to fusion event.	TUFT1-KMT2E seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TUFT1-KMT2E seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TUFT1-KMT2E seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TUFT1-KMT2E seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KMT2E-TUFT1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KMT2E-TUFT1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:104748372/chr7:151542133)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across TUFT1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across KMT2E (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000353024	TUFT1	chr1	151538704	+	ENST00000311117	KMT2E	chr7	104749389	+	3226	365	44	2473	809
ENST00000353024	TUFT1	chr1	151538704	+	ENST00000334914	KMT2E	chr7	104749389	+	1502	365	44	1501	486
ENST00000353024	TUFT1	chr1	151538704	+	ENST00000257745	KMT2E	chr7	104749389	+	3225	365	44	2473	809
ENST00000353024	TUFT1	chr1	151538704	+	ENST00000334877	KMT2E	chr7	104749389	+	3376	365	44	2347	767
ENST00000392712	TUFT1	chr1	151538704	+	ENST00000311117	KMT2E	chr7	104749389	+	3238	377	44	2485	813
ENST00000392712	TUFT1	chr1	151538704	+	ENST00000334914	KMT2E	chr7	104749389	+	1514	377	44	1513	490
ENST00000392712	TUFT1	chr1	151538704	+	ENST00000257745	KMT2E	chr7	104749389	+	3237	377	44	2485	813
ENST00000392712	TUFT1	chr1	151538704	+	ENST00000334877	KMT2E	chr7	104749389	+	3388	377	44	2359	771
ENST00000368849	TUFT1	chr1	151538704	+	ENST00000311117	KMT2E	chr7	104749389	+	3403	542	44	2650	868
ENST00000368849	TUFT1	chr1	151538704	+	ENST00000334914	KMT2E	chr7	104749389	+	1679	542	44	1678	545
ENST00000368849	TUFT1	chr1	151538704	+	ENST00000257745	KMT2E	chr7	104749389	+	3402	542	44	2650	868
ENST00000368849	TUFT1	chr1	151538704	+	ENST00000334877	KMT2E	chr7	104749389	+	3553	542	44	2524	826
ENST00000368848	TUFT1	chr1	151538704	+	ENST00000311117	KMT2E	chr7	104749389	+	3325	464	41	2572	843
ENST00000368848	TUFT1	chr1	151538704	+	ENST00000334914	KMT2E	chr7	104749389	+	1601	464	41	1600	520
ENST00000368848	TUFT1	chr1	151538704	+	ENST00000257745	KMT2E	chr7	104749389	+	3324	464	41	2572	843
ENST00000368848	TUFT1	chr1	151538704	+	ENST00000334877	KMT2E	chr7	104749389	+	3475	464	41	2446	801
ENST00000538902	TUFT1	chr1	151538704	+	ENST00000311117	KMT2E	chr7	104749389	+	3538	677	134	2785	883
ENST00000538902	TUFT1	chr1	151538704	+	ENST00000334914	KMT2E	chr7	104749389	+	1814	677	134	1813	560
ENST00000538902	TUFT1	chr1	151538704	+	ENST00000257745	KMT2E	chr7	104749389	+	3537	677	134	2785	883
ENST00000538902	TUFT1	chr1	151538704	+	ENST00000334877	KMT2E	chr7	104749389	+	3688	677	134	2659	841

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000353024	ENST00000311117	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.002868898	0.9971311
ENST00000353024	ENST00000334914	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.005500516	0.99449944
ENST00000353024	ENST00000257745	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.002916334	0.9970836
ENST00000353024	ENST00000334877	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.00277151	0.99722844
ENST00000392712	ENST00000311117	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.004215746	0.9957842
ENST00000392712	ENST00000334914	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.007065384	0.99293464
ENST00000392712	ENST00000257745	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.004272044	0.99572796
ENST00000392712	ENST00000334877	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.00358033	0.99641967
ENST00000368849	ENST00000311117	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.003210669	0.99678934
ENST00000368849	ENST00000334914	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.011154417	0.9888455
ENST00000368849	ENST00000257745	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.00325446	0.99674547
ENST00000368849	ENST00000334877	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.003358535	0.9966415
ENST00000368848	ENST00000311117	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.006237788	0.9937622
ENST00000368848	ENST00000334914	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.017255086	0.9827449
ENST00000368848	ENST00000257745	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.00629928	0.99370074
ENST00000368848	ENST00000334877	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.005266387	0.9947336
ENST00000538902	ENST00000311117	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.004299493	0.99570054
ENST00000538902	ENST00000334914	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.021014545	0.9789854
ENST00000538902	ENST00000257745	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.004340447	0.99565953
ENST00000538902	ENST00000334877	TUFT1	chr1	151538704	+	KMT2E	chr7	104749389	+	0.004516451	0.9954835

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TUFT1-KMT2E

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
TUFT1	chr1	151538704	KMT2E	chr7	104749389	365	107	SQSPTALYSSPPEVSLLEYRKRQREA
TUFT1	chr1	151538704	KMT2E	chr7	104749389	377	111	SQSPTALYSSPPEVSLLEYRKRQREA
TUFT1	chr1	151538704	KMT2E	chr7	104749389	464	141	SQSPTALYSSPPEVSLLEYRKRQREA
TUFT1	chr1	151538704	KMT2E	chr7	104749389	542	166	SQSPTALYSSPPEVSLLEYRKRQREA
TUFT1	chr1	151538704	KMT2E	chr7	104749389	677	181	SQSPTALYSSPPEVSLLEYRKRQREA

Top

Potential FusionNeoAntigen Information of TUFT1-KMT2E in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

TUFT1-KMT2E_151538704_104749389.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:03	SPPEVSLL	0.9258	0.9153	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B18:01	PEVSLLEY	0.9109	0.8613	11	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:04	SPPEVSLL	0.7544	0.932	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:02	SPPEVSLL	0.7544	0.932	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:22	ALYSSPPEV	0.9991	0.7567	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:24	ALYSSPPEV	0.9989	0.7623	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:30	ALYSSPPEV	0.9989	0.7623	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:13	ALYSSPPEV	0.9989	0.8146	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:60	ALYSSPPEV	0.9989	0.7395	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:67	ALYSSPPEV	0.9989	0.7623	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:11	ALYSSPPEV	0.9988	0.7731	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:27	ALYSSPPEV	0.9987	0.7484	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:21	ALYSSPPEV	0.9986	0.8421	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:16	ALYSSPPEV	0.9986	0.6788	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:38	ALYSSPPEV	0.9979	0.7808	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:04	ALYSSPPEV	0.9949	0.6727	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:17	YSSPPEVSL	0.9934	0.9381	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:17	ALYSSPPEV	0.9906	0.5851	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:16	YSSPPEVSL	0.989	0.6058	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:08	YSSPPEVSL	0.9856	0.9292	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:10	YSSPPEVSL	0.9848	0.7487	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:35	ALYSSPPEV	0.9836	0.7971	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:03	YSSPPEVSL	0.9778	0.9577	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B57:03	YSSPPEVSL	0.9501	0.9605	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:29	ALYSSPPEV	0.9491	0.7629	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:04	YSSPPEVSL	0.9435	0.9766	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:02	YSSPPEVSL	0.9435	0.9766	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:20	ALYSSPPEV	0.9346	0.7671	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:01	YSSPPEVSL	0.9345	0.9514	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:05	YSSPPEVSL	0.9326	0.7455	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B58:01	YSSPPEVSL	0.9237	0.9069	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:13	YSSPPEVSL	0.9005	0.8172	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:21	YSSPPEVSL	0.9004	0.8329	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B58:02	YSSPPEVSL	0.8923	0.9497	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:37	YSSPPEVSL	0.8692	0.8368	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B14:02	YSSPPEVSL	0.8623	0.7477	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B14:01	YSSPPEVSL	0.8623	0.7477	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:08	PPEVSLLEY	0.8243	0.8502	10	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B52:01	YSSPPEVSL	0.7518	0.9258	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A30:08	ALYSSPPEV	0.7355	0.7931	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B13:01	YSSPPEVSL	0.4599	0.9236	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B13:01	ALYSSPPEV	0.1528	0.9891	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B13:02	ALYSSPPEV	0.1131	0.7619	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B48:01	ALYSSPPEV	0.0519	0.6068	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B52:01	ALYSSPPEV	0.025	0.9878	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:16	YSSPPEVSLL	0.9945	0.5846	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:13	ALYSSPPEVS	0.9703	0.7897	5	15
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:01	SPPEVSLLEY	0.9686	0.7849	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:08	SPPEVSLLEY	0.9513	0.7436	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:21	TALYSSPPEV	0.9444	0.7551	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:22	TALYSSPPEV	0.9374	0.5941	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:02	SPPEVSLLEY	0.936	0.8539	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:38	TALYSSPPEV	0.9343	0.7565	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:60	TALYSSPPEV	0.9339	0.6172	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:35	TALYSSPPEV	0.9336	0.6793	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:30	TALYSSPPEV	0.9301	0.6474	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:11	TALYSSPPEV	0.9301	0.6609	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:24	TALYSSPPEV	0.9301	0.6474	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:67	TALYSSPPEV	0.9301	0.6474	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:16	TALYSSPPEV	0.9277	0.5543	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:13	TALYSSPPEV	0.9215	0.7601	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:29	TALYSSPPEV	0.9054	0.6463	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:27	TALYSSPPEV	0.9039	0.6646	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:20	TALYSSPPEV	0.8997	0.6525	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:04	TALYSSPPEV	0.8841	0.602	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:22	ALYSSPPEVSL	0.9982	0.7457	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:13	ALYSSPPEVSL	0.9975	0.7864	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:04	ALYSSPPEVSL	0.9961	0.6226	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:27	ALYSSPPEVSL	0.9954	0.7209	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:67	ALYSSPPEVSL	0.9951	0.7463	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:24	ALYSSPPEVSL	0.9951	0.7463	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:21	ALYSSPPEVSL	0.9951	0.8398	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:30	ALYSSPPEVSL	0.9951	0.7463	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:60	ALYSSPPEVSL	0.9949	0.7185	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:11	ALYSSPPEVSL	0.9949	0.757	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:08	SSPPEVSLLEY	0.9947	0.8257	8	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:16	ALYSSPPEVSL	0.9914	0.6528	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:38	ALYSSPPEVSL	0.9833	0.7539	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:35	ALYSSPPEVSL	0.9755	0.7722	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:29	ALYSSPPEVSL	0.951	0.7442	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:20	ALYSSPPEVSL	0.9434	0.7511	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:08	SSPPEVSL	0.9999	0.9611	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:17	SSPPEVSL	0.9997	0.939	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:30	SSPPEVSL	0.9993	0.96	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:30	SPPEVSLL	0.9649	0.9548	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:17	SPPEVSLL	0.9633	0.9273	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:12	SPPEVSLL	0.7544	0.932	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:10	SPPEVSLL	0.6329	0.9425	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:08	YSSPPEVSL	0.9999	0.9447	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:06	YSSPPEVSL	0.9999	0.9363	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:07	YSSPPEVSL	0.9999	0.99	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:04	YSSPPEVSL	0.9999	0.9298	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:19	YSSPPEVSL	0.9999	0.9927	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:06	YSSPPEVSL	0.9998	0.9018	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C05:09	YSSPPEVSL	0.9997	0.93	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:04	YSSPPEVSL	0.9997	0.9573	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:13	YSSPPEVSL	0.9997	0.9573	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:10	YSSPPEVSL	0.9996	0.8398	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:03	YSSPPEVSL	0.9996	0.9944	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:07	YSSPPEVSL	0.9996	0.8649	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:04	YSSPPEVSL	0.9996	0.9956	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:12	YSSPPEVSL	0.9994	0.8875	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:15	YSSPPEVSL	0.9994	0.9688	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:16	YSSPPEVSL	0.9994	0.9558	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:14	YSSPPEVSL	0.9994	0.8618	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:17	YSSPPEVSL	0.9993	0.9224	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:05	ALYSSPPEV	0.999	0.5807	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:01	ALYSSPPEV	0.9989	0.7623	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:07	ALYSSPPEV	0.9988	0.7908	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:14	YSSPPEVSL	0.9984	0.9833	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:07	SSPPEVSLL	0.9982	0.9893	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:08	SSPPEVSLL	0.9981	0.9566	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:19	SSPPEVSLL	0.9978	0.9945	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:05	YSSPPEVSL	0.9973	0.969	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:13	YSSPPEVSL	0.9969	0.9493	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:06	SSPPEVSLL	0.9966	0.948	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:21	YSSPPEVSL	0.9955	0.9519	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:03	YSSPPEVSL	0.9954	0.9816	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:03	ALYSSPPEV	0.9946	0.9962	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:27	YSSPPEVSL	0.9942	0.9652	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:29	YSSPPEVSL	0.9938	0.9625	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C05:09	SSPPEVSLL	0.9935	0.9306	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:10	YSSPPEVSL	0.993	0.9609	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:30	YSSPPEVSL	0.9927	0.9423	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:07	SSPPEVSLL	0.992	0.8758	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:10	SSPPEVSLL	0.9919	0.8642	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:67	YSSPPEVSL	0.9912	0.9557	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:80	YSSPPEVSL	0.9912	0.9557	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:08	YSSPPEVSL	0.9903	0.7004	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:46	YSSPPEVSL	0.9856	0.8974	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:95	YSSPPEVSL	0.9842	0.8007	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:06	SSPPEVSLL	0.9798	0.919	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:19	YSSPPEVSL	0.9743	0.7815	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:17	SSPPEVSLL	0.9659	0.9358	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:09	YSSPPEVSL	0.9569	0.6601	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:03	SSPPEVSLL	0.9547	0.9946	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:04	SSPPEVSLL	0.9511	0.9959	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:12	YSSPPEVSL	0.9435	0.9766	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:10	YSSPPEVSL	0.9404	0.9507	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:06	ALYSSPPEV	0.9357	0.9526	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:12	SSPPEVSLL	0.9216	0.8874	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:06	YSSPPEVSL	0.9213	0.9771	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:06	ALYSSPPEV	0.9181	0.9517	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:04	SSPPEVSLL	0.9147	0.9667	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:13	SSPPEVSLL	0.9147	0.9667	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:14	SSPPEVSLL	0.9125	0.8998	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:30	SSPPEVSLL	0.9049	0.9587	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:07	YSSPPEVSL	0.8821	0.7107	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C05:09	ALYSSPPEV	0.8387	0.9585	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:14	ALYSSPPEV	0.8142	0.9345	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B14:03	YSSPPEVSL	0.789	0.8305	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:10	ALYSSPPEV	0.7618	0.9412	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:07	ALYSSPPEV	0.7411	0.931	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:03	SSPPEVSLL	0.7389	0.9895	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:04	ALYSSPPEV	0.7247	0.9776	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B07:12	YSSPPEVSL	0.5873	0.5207	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:13	SSPPEVSLL	0.5798	0.9626	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:19	SSPPEVSLL	0.5578	0.8295	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:29	SSPPEVSLL	0.5413	0.9757	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:06	ALYSSPPEV	0.471	0.9737	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:06	SSPPEVSLL	0.4381	0.9772	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:04	ALYSSPPEV	0.3774	0.9706	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:13	ALYSSPPEV	0.3774	0.9706	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:07	SSPPEVSLL	0.3256	0.7039	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:17	ALYSSPPEV	0.2344	0.9717	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:13	ALYSSPPEV	0.0532	0.9812	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:29	ALYSSPPEV	0.0531	0.9822	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:08	YSSPPEVSLL	0.9998	0.9418	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:06	YSSPPEVSLL	0.9998	0.9389	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:07	YSSPPEVSLL	0.9998	0.9897	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:19	YSSPPEVSLL	0.9998	0.9921	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:06	YSSPPEVSLL	0.9986	0.9109	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:04	YSSPPEVSLL	0.9982	0.9616	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:13	YSSPPEVSLL	0.9982	0.9616	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:17	YSSPPEVSLL	0.9978	0.92	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:03	YSSPPEVSLL	0.9865	0.9817	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:30	YSSPPEVSLL	0.985	0.9421	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:06	YSSPPEVSLL	0.9743	0.976	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:31	SPPEVSLLEY	0.968	0.7618	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:13	LYSSPPEVSL	0.9548	0.926	6	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:29	LYSSPPEVSL	0.9543	0.9661	6	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:01	TALYSSPPEV	0.9301	0.6474	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:05	ALYSSPPEVSL	0.9982	0.5778	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:07	ALYSSPPEVSL	0.9958	0.7428	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:01	ALYSSPPEVSL	0.9951	0.7463	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:17	SSPPEVSL	0.9999	0.986	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:03	SSPPEVSL	0.9999	0.9096	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:02	SSPPEVSL	0.9997	0.9372	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:02	SPPEVSLL	0.9382	0.9248	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:03	SPPEVSLL	0.9163	0.8951	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B18:05	PEVSLLEY	0.9109	0.8613	11	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B18:11	PEVSLLEY	0.9098	0.8912	11	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:09	SPPEVSLL	0.7544	0.932	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B67:01	SPPEVSLL	0.6892	0.7214	9	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B07:13	SSPPEVSL	0.6802	0.8683	8	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:67	YSSPPEVSL	0.9999	0.9876	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:03	YSSPPEVSL	0.9999	0.9932	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:04	YSSPPEVSL	0.9999	0.9932	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:09	YSSPPEVSL	0.9999	0.9298	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:05	YSSPPEVSL	0.9999	0.9376	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:17	YSSPPEVSL	0.9998	0.9808	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:02	YSSPPEVSL	0.9998	0.9084	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C16:04	YSSPPEVSL	0.9998	0.981	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:05	YSSPPEVSL	0.9998	0.9212	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:04	YSSPPEVSL	0.9997	0.8843	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C05:01	YSSPPEVSL	0.9997	0.93	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:02	YSSPPEVSL	0.9997	0.9656	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:02	YSSPPEVSL	0.9997	0.9775	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:03	YSSPPEVSL	0.9997	0.8863	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:03	YSSPPEVSL	0.9997	0.977	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:01	YSSPPEVSL	0.9996	0.8649	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C18:01	YSSPPEVSL	0.9996	0.8492	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:06	YSSPPEVSL	0.9996	0.9895	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:02	YSSPPEVSL	0.9994	0.9688	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:06	YSSPPEVSL	0.9993	0.9931	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:03	YSSPPEVSL	0.9992	0.9011	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:02	YSSPPEVSL	0.9992	0.9207	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:03	ALYSSPPEV	0.9992	0.8283	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:17	YSSPPEVSL	0.9991	0.9948	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:02	YSSPPEVSL	0.9991	0.9948	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C16:02	YSSPPEVSL	0.9988	0.9904	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C16:01	YSSPPEVSL	0.9988	0.9786	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:14	ALYSSPPEV	0.9986	0.782	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:06	ALYSSPPEV	0.9986	0.8421	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:03	SSPPEVSLL	0.9977	0.9948	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:04	SSPPEVSLL	0.9977	0.9948	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:04	YSSPPEVSL	0.9972	0.9137	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:02	SSPPEVSLL	0.9961	0.9237	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:11	YSSPPEVSL	0.996	0.9445	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:05	SSPPEVSLL	0.9958	0.9325	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:17	SSPPEVSLL	0.9958	0.9846	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:05	SSPPEVSLL	0.9955	0.9585	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:01	YSSPPEVSL	0.9954	0.9816	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C18:01	SSPPEVSLL	0.9942	0.8697	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:22	YSSPPEVSL	0.9936	0.7998	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C05:01	SSPPEVSLL	0.9935	0.9306	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:17	YSSPPEVSL	0.9935	0.9722	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:03	SSPPEVSLL	0.9928	0.8934	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:67	SSPPEVSLL	0.9922	0.987	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:01	SSPPEVSLL	0.992	0.8758	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:02	YSSPPEVSL	0.9912	0.9557	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:43	YSSPPEVSL	0.9884	0.9393	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:08	YSSPPEVSL	0.9869	0.9397	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:73	YSSPPEVSL	0.9849	0.9543	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:06	SSPPEVSLL	0.983	0.9919	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:11	YSSPPEVSL	0.9829	0.7204	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:01	YSSPPEVSL	0.9813	0.7513	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:30	YSSPPEVSL	0.9808	0.7719	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:03	SSPPEVSLL	0.9788	0.9072	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:02	SSPPEVSLL	0.9777	0.9342	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B57:04	YSSPPEVSL	0.9714	0.664	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B58:06	YSSPPEVSL	0.9692	0.7774	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:13	YSSPPEVSL	0.9689	0.9599	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:02	ALYSSPPEV	0.968	0.9169	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:06	SSPPEVSLL	0.967	0.9943	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:23	YSSPPEVSL	0.9616	0.9201	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:04	SSPPEVSLL	0.9575	0.914	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B57:02	YSSPPEVSL	0.9543	0.8437	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:05	ALYSSPPEV	0.9501	0.939	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C12:03	SSPPEVSLL	0.9478	0.9789	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C16:04	SSPPEVSLL	0.947	0.9805	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B39:02	YSSPPEVSL	0.9447	0.8287	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:09	YSSPPEVSL	0.9435	0.9766	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B67:01	YSSPPEVSL	0.9421	0.86	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A69:01	YSSPPEVSL	0.9178	0.8838	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:14	YSSPPEVSL	0.9024	0.7192	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:06	YSSPPEVSL	0.9004	0.8329	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:02	YSSPPEVSL	0.8909	0.9851	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:10	YSSPPEVSL	0.8909	0.9851	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:09	YSSPPEVSL	0.8891	0.6021	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:04	ALYSSPPEV	0.8665	0.9555	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C17:01	YSSPPEVSL	0.8662	0.8981	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:02	SSPPEVSLL	0.8533	0.9953	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:17	SSPPEVSLL	0.8533	0.9953	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C16:02	SSPPEVSLL	0.8488	0.9923	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:73	ALYSSPPEV	0.844	0.9542	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C05:01	ALYSSPPEV	0.8387	0.9585	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:08	YSSPPEVSL	0.8314	0.9925	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:03	ALYSSPPEV	0.8212	0.933	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:22	SSPPEVSLL	0.7436	0.792	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:30	ALYSSPPEV	0.7432	0.8697	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C04:01	ALYSSPPEV	0.7411	0.931	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:01	SSPPEVSLL	0.7389	0.9895	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B57:02	SSPPEVSLL	0.7292	0.8831	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C18:01	ALYSSPPEV	0.7221	0.9353	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B07:13	YSSPPEVSL	0.7157	0.8499	7	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:04	SSPPEVSLL	0.6777	0.9353	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:06	ALYSSPPEV	0.6158	0.9925	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C17:01	SSPPEVSLL	0.4637	0.8951	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C17:01	ALYSSPPEV	0.4417	0.9731	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:08	ALYSSPPEV	0.3761	0.9931	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C06:08	SSPPEVSLL	0.3689	0.9923	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:03	ALYSSPPEV	0.3581	0.9675	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:02	ALYSSPPEV	0.2205	0.9698	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B07:13	SSPPEVSLL	0.0495	0.8575	8	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B40:21	ALYSSPPEV	0.0441	0.5077	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C07:04	ALYSSPPEV	0.0355	0.9705	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B07:13	ALYSSPPEV	0.0083	0.8673	5	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:04	YSSPPEVSLL	0.9998	0.9926	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:03	YSSPPEVSLL	0.9998	0.9926	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:02	YSSPPEVSLL	0.9997	0.9117	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C15:05	YSSPPEVSLL	0.9997	0.917	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:05	YSSPPEVSLL	0.9996	0.9365	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:17	YSSPPEVSLL	0.9995	0.9809	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:03	YSSPPEVSLL	0.9993	0.8983	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C01:02	YSSPPEVSLL	0.9986	0.9187	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C16:02	YSSPPEVSLL	0.9975	0.9905	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:06	YSSPPEVSLL	0.9956	0.9924	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B57:02	YSSPPEVSLL	0.9908	0.8217	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C03:67	LYSSPPEVSL	0.9908	0.9859	6	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C08:01	YSSPPEVSLL	0.9865	0.9817	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C14:02	LYSSPPEVSL	0.9842	0.9522	6	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C14:03	LYSSPPEVSL	0.9842	0.9522	6	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:02	YSSPPEVSLL	0.9813	0.9832	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C02:10	YSSPPEVSLL	0.9813	0.9832	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:77	SPPEVSLLEY	0.9686	0.7849	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:23	SPPEVSLLEY	0.9676	0.7183	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:03	TALYSSPPEV	0.9653	0.7265	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:20	SPPEVSLLEY	0.9646	0.8239	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-C17:01	YSSPPEVSLL	0.9525	0.8784	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:13	YSSPPEVSLL	0.9515	0.9508	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:06	TALYSSPPEV	0.9444	0.7551	4	14
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:11	SPPEVSLLEY	0.9427	0.8031	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:08	SPPEVSLLEY	0.9099	0.748	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:11	SPPEVSLLEY	0.9044	0.7447	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:43	SPPEVSLLEY	0.896	0.7498	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:24	SPPEVSLLEY	0.8676	0.7986	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:30	SPPEVSLLEY	0.8662	0.6165	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B35:17	SPPEVSLLEY	0.8662	0.6165	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B07:13	YSSPPEVSLL	0.8381	0.8381	7	17
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B18:07	SPPEVSLLEY	0.3586	0.8369	9	19
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:73	ALYSSPPEVSL	0.9996	0.9172	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-B15:30	ALYSSPPEVSL	0.9991	0.7877	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:03	ALYSSPPEVSL	0.9972	0.817	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:14	ALYSSPPEVSL	0.9955	0.7389	5	16
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	HLA-A02:06	ALYSSPPEVSL	0.9951	0.8398	5	16

Top

Potential FusionNeoAntigen Information of TUFT1-KMT2E in HLA II

TUFT1-KMT2E_151538704_104749389.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1102	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1102	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1114	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1116	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1116	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1120	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1121	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1121	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1136	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1136	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1148	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1155	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1165	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1165	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1168	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1170	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1170	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1186	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1301	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1301	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1302	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1304	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1304	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1308	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1315	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1315	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1316	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1317	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1317	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1319	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1320	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1320	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1322	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1322	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1323	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1327	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1327	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1329	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1332	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1334	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1335	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1335	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1339	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1343	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1348	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1351	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1351	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1352	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1352	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1353	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1357	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1357	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1359	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1359	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1361	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1361	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1364	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1364	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1368	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1368	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1369	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1369	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1370	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1371	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1371	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1372	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1373	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1374	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1375	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1376	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1378	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1378	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1379	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1379	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1380	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1380	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1383	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1383	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1384	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1387	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1387	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1391	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1391	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1392	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1392	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1393	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1393	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1397	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1398	PEVSLLEYRKRQREA	11	26
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1398	PPEVSLLEYRKRQRE	10	25
TUFT1-KMT2E	chr1	151538704	chr7	104749389	365	DRB1-1399	PEVSLLEYRKRQREA	11	26

Top

Fusion breakpoint peptide structures of TUFT1-KMT2E

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5843	LYSSPPEVSLLEYR	TUFT1	KMT2E	chr1	151538704	chr7	104749389	365

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TUFT1-KMT2E

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5843	LYSSPPEVSLLEYR	-8.50832	-8.70402
HLA-B14:02	3BVN	5843	LYSSPPEVSLLEYR	-5.75992	-6.51552
HLA-B52:01	3W39	5843	LYSSPPEVSLLEYR	-6.19183	-6.38753
HLA-B52:01	3W39	5843	LYSSPPEVSLLEYR	-5.46727	-6.22287
HLA-A24:02	5HGA	5843	LYSSPPEVSLLEYR	-7.7823	-7.978
HLA-A24:02	5HGA	5843	LYSSPPEVSLLEYR	-6.90283	-7.65843
HLA-B27:05	6PYJ	5843	LYSSPPEVSLLEYR	-8.56023	-8.75593
HLA-B44:05	3DX8	5843	LYSSPPEVSLLEYR	-5.60395	-5.79965
HLA-B44:05	3DX8	5843	LYSSPPEVSLLEYR	-3.71581	-4.47141
HLA-A02:01	6TDR	5843	LYSSPPEVSLLEYR	-4.77323	-4.96893

Top

Vaccine Design for the FusionNeoAntigens of TUFT1-KMT2E

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
TUFT1-KMT2E	chr1	151538704	chr7	104749389	10	19	PPEVSLLEY	CCACCTGAGGTTTCTCTATTAGAATAC
TUFT1-KMT2E	chr1	151538704	chr7	104749389	11	19	PEVSLLEY	CCTGAGGTTTCTCTATTAGAATAC
TUFT1-KMT2E	chr1	151538704	chr7	104749389	4	14	TALYSSPPEV	ACAGCCCTGTACAGCAGCCCACCTGAGGTT
TUFT1-KMT2E	chr1	151538704	chr7	104749389	5	14	ALYSSPPEV	GCCCTGTACAGCAGCCCACCTGAGGTT
TUFT1-KMT2E	chr1	151538704	chr7	104749389	5	15	ALYSSPPEVS	GCCCTGTACAGCAGCCCACCTGAGGTTTCT
TUFT1-KMT2E	chr1	151538704	chr7	104749389	5	16	ALYSSPPEVSL	GCCCTGTACAGCAGCCCACCTGAGGTTTCTCTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	6	16	LYSSPPEVSL	CTGTACAGCAGCCCACCTGAGGTTTCTCTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	7	16	YSSPPEVSL	TACAGCAGCCCACCTGAGGTTTCTCTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	7	17	YSSPPEVSLL	TACAGCAGCCCACCTGAGGTTTCTCTATTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	8	16	SSPPEVSL	AGCAGCCCACCTGAGGTTTCTCTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	8	17	SSPPEVSLL	AGCAGCCCACCTGAGGTTTCTCTATTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	8	19	SSPPEVSLLEY	AGCAGCCCACCTGAGGTTTCTCTATTAGAATAC
TUFT1-KMT2E	chr1	151538704	chr7	104749389	9	17	SPPEVSLL	AGCCCACCTGAGGTTTCTCTATTA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	9	19	SPPEVSLLEY	AGCCCACCTGAGGTTTCTCTATTAGAATAC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
TUFT1-KMT2E	chr1	151538704	chr7	104749389	10	25	PPEVSLLEYRKRQRE	CCACCTGAGGTTTCTCTATTAGAATACCGTAAGAGACAACGTGAA
TUFT1-KMT2E	chr1	151538704	chr7	104749389	11	26	PEVSLLEYRKRQREA	CCTGAGGTTTCTCTATTAGAATACCGTAAGAGACAACGTGAAGCT

Top

Information of the samples that have these potential fusion neoantigens of TUFT1-KMT2E

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
COAD	TUFT1-KMT2E	chr1	151538704	ENST00000353024	chr7	104749389	ENST00000257745	TCGA-A6-5660-01A

Top

Potential target of CAR-T therapy development for TUFT1-KMT2E

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to TUFT1-KMT2E

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to TUFT1-KMT2E

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)